厄贝沙坦氢氯噻嗪、硝苯地平、瑞舒伐他汀联合用药在老年高血压合并高血脂患者心脏介入术后预防的应用效果

Application effect of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin in the prevention of elderly patients with hypertension and hyperlipidemia after cardiac intervention

目的探讨厄贝沙坦氢氯噻嗪、硝苯地平、瑞舒伐他汀联合用药在老年高血压合并高血脂患者经皮冠脉介入术(PCI)后预防的应用效果。方法选取2019年1月至12月巴彦淖尔市医院收治的178例PCI术后的老年高血压合并高血脂患者作为研究对象。采用掷硬币法将其分为观察组(92例)与对照组(86例)。观察组预防性给予厄贝沙坦氢氯噻嗪、硝苯地平、瑞舒伐他汀联合用药,对照组预防性给予硝苯地平、瑞舒伐他汀联合用药。比较两组患者在出院日及术后6、12、18、24个月血压(BP)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇(TC)、小而密低密度脂蛋白胆固醇(sd LDL-C)、脂蛋白[Lp(a)]、超敏C反应蛋白(hs-CRP)、血浆D-二聚体(D-D)表达水平,记录不良心血管事件发生情况。结果观察组患者术后18个月的hs-CRP表达水平低于对照组,差异有统计学意义(P<0.05)。观察组术后24个月的BP、sd LDL-C、Lp(a)、hs-CRP、D-D均低于对照组,差异有统计学意义(P<0.05)。观察组的不良心血管事件的发生率低于对照组,差异有统计学意义(P<0.05)。结论PCI术后预防性给予厄贝沙坦氢氯噻嗪、硝苯地平、瑞舒伐他汀联合长期用药,可有效降低因高血压合并高血脂导致出现严重动脉硬化的老年患者的血压和血脂水平,降低不良心血管事件发生率。

Objective To explore the application effect of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin in the prevention of elderly patients with hypertension and hyperlipidemia after percutaneous coronary intervention(PCI).Methods A total of 178 elderly patients with hypertension and hyperlipidemia after PCI who were admitted to Bayannur Hospital from January to December 2019 were selected as the research objects.They were divided into the observation group(92 cases)and the control group(86 cases)by tossing a coin.The observation group was treated with Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin,and the control group was treated with Nifedipine and Rosuvastatin.Blood pressure(BP),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),triglyceride(TG),total cholesterol(TC),small dense low density lipoprotein cholesterol(sd LDL-C),lipoprotein a(Lp[a]),high-sensitivity C-reactive protein(hs-CRP),plasma D-dimer(D-D)expression levels were compared between the two groups on the day of discharge and 6,12,18,24 months after operation,and adverse cardiovascular events were recorded.Results The expression level of hs-CRP in the observation group was lower than that in the control group 18 months after operation,and the difference was statistically significant(P<0.05).The BP,sd LDL-C,Lp(a),hs-CRP and D-D of the observation group were lower than those of the control group 24 months after operation,and the differences were statistically significant(P<0.05).The incidence of adverse cardiovascular events in the observation group was lower than that in the control group,with statistically significant difference(P<0.05).Conclusion The prophylactic administration of Irbesartan Hydrochlorothiazide,Nifedipine and Rosuvastatin after PCI can effectively reduce the blood pressure and blood lipid levels in elderly patients with severe arteriosclerosis caused by hypertension and hyperlipidemia,and reduce the incidence of adverse cardiovascular events.